Home›People›John O'Malley
John O'Malley

John O'Malley

Chief medical officer at Matchpoint Therapeutics.

Executive
Updated Nov 20, 2026·Latest SEC filing Nov 20, 2026·Suggest an edit

About John O'Malley

John O'Malley is chief medical officer at Matchpoint Therapeutics, which develops oral medicines for autoimmune and inflammatory diseases. He joined in October 2026 as Matchpoint advanced its lead program into clinical development. He previously was vice president, head of translational medicine and autoimmune disease program leader at CRISPR Therapeutics. There, he guided a clinical-stage CAR T-cell therapy and managed clinical translation work.

At Sanofi, he led amlitelimab’s clinical development across all indications, including mid- and late-stage trials. He also helped expand Dupixent into pediatric atopic dermatitis and prurigo nodularis as a senior clinical director. Earlier, he was an assistant professor of dermatology at Brigham and Women’s Hospital and studied human T-cell immunology. He treated skin lymphoma patients at Dana-Farber. He completed a postdoctoral dermatology fellowship at Harvard Medical School and served as chief dermatology resident at NewYork-Presbyterian Hospital and Columbia University Irving Medical Center. He earned an M.D. and Ph.D. from Indiana University and a B.S., summa cum laude, from Notre Dame.

Experience

This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name John O'Malley in the role, so the role may have started earlier or lasted longer.

Matchpoint Therapeutics Inc. Current
Chief Medical Officer
2026 – Present · Watertown, MA
Matchpoint develops oral drugs that bind hard-to-treat protein targets in immune diseases.
CRISPR Therapeutics
Vice President, Head of Translational Medicine and Autoimmune Disease Program Leader
Sanofi
Global Clinical Leader for amlitelimab
Senior Clinical Director
Brigham and Women’s Hospital
Assistant Professor of Dermatology
Dana-Farber Cancer Institute
NewYork-Presbyterian Hospital / Columbia University Irving Medical Center
Chief Dermatology Resident

Key Colleagues at Startups

The people John O'Malley works with at each company, as listed on that company's latest Form D.

Matchpoint Therapeutics Inc. · Form D, Nov 20, 2026
Andre Turenne
Andre Turenne
Director; President & Chief Executive Officer
BM
Brian Matesic
Director; Principal, Norwest
KP
Kanishka Pothula
Director; Managing Partner, Nextech
JH
Jason Hafler
Director; Managing Director, Sanofi Ventures
BB
Bruce Booth
Chairman; Partner, Atlas Venture
DB
Daniel Becker
Director; Managing Director, Access Biotechnology
DN
Jared Cumming
Jared Cumming
Chief Scientific Officer

Sources

  1. SECMatchpoint Therapeutics Inc. Form D, filed Nov 20, 2026
  2. P2Matchpoint Therapeutics appointment release